NSE filing, NSE: KILITCH. Summary written from the filing by ALFA Finder's alert engine.
Kilitch Drugs(I) Ltd: key numbers
- Share price
- ₹214.97
- Market cap
- ₹751.6 Cr
- Revenue (annual)
- ₹235.5 Cr
- Net profit (annual)
- ₹30.17 Cr
- P/E (TTM)
- 25.0×Sector 46.1×
- Promoter holding
- 63.77%+0.00% QoQ
- FII holding
- 0.10%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kilitch Drugs(I) Ltd
All →Kilitch Drugs(I) Annual General Meeting
Kilitch Drugs' EGM notice seeks shareholder approval for selling its Ethiopian material subsidiary and converting subsidiary debt into equity. It also proposes two independent director appointments.
Kilitch Drugs(I) Merger & Restructuring Worth ₹131.6 Cr
Kilitch Drugs will divest its entire Ethiopian subsidiary stake to HarmeeCare for US$14 million (~₹131.6 Crore). Proceeds will fund debt repayment and Pen plant expansion.
- Value
- ₹131.6 Cr
Kilitch Drugs(I) Merger & Restructuring Worth ₹120.8 Cr
Kilitch Drugs will divest its 100% stake in subsidiary Kilitch Estro Biotech PLC for USD 12.855 million (approx. ₹120.84 Crore).
- Value
- ₹120.8 Cr
- From
- HarmeeCare Pharmaceuticals
Kilitch Drugs(I) Management Change
Kilitch Drugs' Non-Executive Independent Director Mr. Venkita Subramanian Rajan resigned effective 21 Oct 2026. He also stepped down from the Audit, NCR, and SRC Committees citing personal commitments.
Kilitch Drugs(I) Annual General Meeting
Kilitch Drugs (India) held its 34th Annual General Meeting on August 27, 2026, transacting four business resolutions including financial statement approval and director re-appointment.
Kilitch Drugs(I) Other Announcement
Kilitch Drugs filed its Monitoring Agency Report for the quarter ended June 30, 2026, concerning its Rights Issue proceeds of Rs. 49.92 Crore.
- Value
- ₹49.92 Cr
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.